Telix Pharmaceuticals Limited

What began in 2015 as a vision to create a truly integrated radiopharmaceutical company has blossomed into Telix Pharmaceuticals, a global leader in the field of precision oncology. Founded by Dr. Christian Behrenbruch and Andreas Kluge, Telix embarked on a journey to harness the power of molecularly targeted radiation (MTR) to revolutionize how cancer is diagnosed and treated. The core idea was simple yet profound: attach a radioactive payload to a molecule that specifically targets cancer cells. This 'theranostic' approach allows for both the imaging of tumors at low doses and the delivery of potent, cell-destroying radiation at higher doses, all while minimizing harm to healthy tissue. This innovative method promised a more personalized and effective path forward for patients with some of the most challenging cancers.

The company's early years were marked by strategic acquisitions and crucial clinical collaborations, building a robust pipeline of products targeting significant unmet needs in prostate, kidney, and brain cancers. A pivotal moment in Telix's story was the regulatory approval of its flagship product, Illuccix®, for prostate cancer imaging. This milestone, first achieved with the U.S. FDA in late 2021 and followed by approvals in Australia and Canada, transformed Telix from a clinical-stage biotech into a commercial powerhouse. The successful launch of Illuccix® not only provided a significant new tool for clinicians but also generated substantial revenue, fueling further research and development across its diverse portfolio. Headquartered in Melbourne, Australia, Telix has expanded its footprint globally, with operations in the United States, Europe, and Japan, including a state-of-the-art manufacturing facility in Belgium. This international presence and vertically integrated model ensure that Telix can deliver its time-sensitive radiopharmaceuticals to patients worldwide, truly delivering on the promise of seeing and treating cancer with precision.